Dexlansoprazole is a proton-pump inhibitor (PPI) used to treat conditions related to excess stomach acid. It is available as a generic medication and marketed under brand names such as Dexilant. In Hong Kong the drug is prescription-only and supplied in pill form at strengths of 30 mg and 60 mg. It belongs to the digestive-health therapeutic class and works by reducing the amount of acid produced in the stomach.
Dexlansoprazole belongs to the PPI group, which irreversibly inhibits the H⁺/K⁺-ATPase enzyme (the gastric proton pump) located on the secretory surface of parietal cells. By blocking this final step of acid production, the medication raises gastric pH and allows inflamed esophageal tissue to heal.
A distinctive feature of dexlansoprazole is its dual delayed-release (DDR) formulation. The pill contains two types of coating that dissolve at different times, creating two separate waves of drug release. This design provides prolonged acid suppression over a 24-hour period and permits flexible dosing (with or without food).
These indications are approved by major regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). In Hong Kong, local health authorities follow similar approvals for prescription use in adult patients.
Helicobacter pylori eradication regimens - several clinical studies have combined dexlansoprazole with antibiotics and shown comparable eradication rates to other PPIs. However, this use is not approved by regulatory agencies and should only be considered under specialist supervision.
Zollinger-Ellison syndrome - case series suggest PPIs, including dexlansoprazole, can control acid hypersecretion, but formal approval is lacking.
Off-label use requires medical supervision and individualized risk assessment.
Absolute contraindications
Known hypersensitivity to dexlansoprazole, other PPIs, or any tablet ingredients.
Relative contraindications / cautions
Severe hepatic impairment (Child-Pugh class C) - dose adjustment may be needed.
Pregnancy and lactation - animal studies show risk; use only if the benefit outweighs potential harm.
Elderly patients - monitor for bone-density loss and magnesium depletion with long-term therapy.
Special populations
Renal dysfunction: No dose adjustment needed for mild to moderate impairment.
Pediatric use: Dexlansoprazole is not approved for children; pediatric dosing is not established.
These effects are typically mild, transient, and often resolve without intervention.
If any of these serious symptoms occur, seek medical attention promptly.
Major interactions
Atazanavir, Ritonavir, Lopinavir/ritonavir - reduced antiviral absorption; avoid co-administration.
Methotrexate (high-dose) - increased serum levels; monitor for toxicity.
Moderate interactions
Clopidogrel - PPIs may diminish antiplatelet effect; consider alternative antiplatelet agents.
Warfarin - possible increase in INR; monitor coagulation parameters.
Pharmacokinetic considerations
Dexlansoprazole is metabolised primarily by CYP2C19 and CYP3A4; inhibitors of these enzymes can raise dexlansoprazole concentrations.
Patients should always inform their healthcare provider of all medicines, supplements, and herbal products before starting dexlansoprazole.
Standard dosing
30 mg once daily for healing of erosive esophagitis or maintenance therapy.
60 mg once daily may be prescribed for severe erosive disease or when higher acid suppression is required.
Special populations
Renal impairment: No dose change needed unless dialysis is required.
Hepatic impairment: Use the lowest effective dose; avoid 60 mg in severe dysfunction.
Administration
Swallow the pill whole with a glass of water.
Do not crush, chew, or split the tablet.
Missed dose
Take the next scheduled dose at the usual time.
Do not double the dose without medical advice.
Overdose
Symptoms may include confusion, drowsiness, or cardiac arrhythmia.
Management is primarily supportive; contact emergency services if overdose is suspected.
Discontinuation
No tapering is required, but abrupt cessation can lead to rebound acid hypersecretion (return of heartburn). Discuss a step-down plan with a clinician if long-term therapy is ending.
This article provides educational information about dexlansoprazole and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Dexlansoprazole’s DDR formulation can be taken with or without food, but using additional antacids may lessen the overall acid-suppressing effect. It's best to separate antacid use by at least two hours from the dexlansoprazole dose unless directed otherwise by a clinician.
Long-term therapy is generally safe when monitored. Healthcare providers should periodically assess magnesium, vitamin B12, and bone density, especially in older adults or those on concurrent medications that affect mineral absorption.
The key difference lies in its dual delayed-release system, which provides two separate drug releases and a longer duration of acid control. This allows once-daily dosing without regard to meals, whereas some other PPIs have stricter timing requirements.
Yes. Dexlansoprazole can reduce the absorption of certain protease inhibitors such as atazanavir and ritonavir, potentially decreasing their effectiveness. Patients on these antivirals should discuss alternative acid-suppression strategies with their physician.
Take the missed dose at the next scheduled time based on your usual local routine. Avoid taking two doses close together; if the missed dose is near the time of the next scheduled dose, simply skip the missed one and continue as directed.
Both strengths are typically round, film-coated tablets but differ in imprint code and colour. In Hong Kong, the 30 mg tablet may be coloured pink with “30” imprinted, while the 60 mg tablet is often white with “60” imprinted. Check the packaging for specific identification.
Weight gain or loss is not a recognized direct effect of dexlansoprazole. However, relief of reflux symptoms may improve appetite, which could indirectly affect weight. Report any unexplained weight changes to your healthcare provider.
The drug can elevate gastric pH, potentially interfering with tests that rely on an acidic environment, such as certain stool occult blood assays. Inform laboratory personnel that you are taking a PPI if a test result seems unexpected.
Coverage varies by individual health plan and clinical indication. Patients should verify eligibility with the Hospital Authority or their private insurer before filling a prescription.
Do not flush tablets down the toilet. Return unused medication to a pharmacy-based take-back program or follow the local Environmental Protection Department guidelines for pharmaceutical waste disposal.
